Literature DB >> 7869036

A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes.

P D Crowe1, B N Walter, K M Mohler, C Otten-Evans, R A Black, C F Ware.   

Abstract

TNF is synthesized as a 26-kD membrane-anchored precursor and is proteolytically processed at the cell surface to yield the mature secreted 17-kD polypeptide. The 80-kD tumor necrosis factor (TNF) receptor (TNFR80) is also proteolytically cleaved at the cell surface (shed), releasing a soluble ligand-binding receptor fragment. Since processing of TNF and TNFR80 occurs concurrently in activated T cells, we asked whether a common protease may be involved. Here, we present evidence that a recently described inhibitor of TNF processing N-(D,L-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl)L- 3-(2'naphthyl)- alanyl-L-alanine, 2-aminoethyl amide (TAPI) also blocks shedding of TNFR80, suggesting that these processes may be coordinately regulated during T cell activation. In addition, studies of murine fibroblasts transfected with human TNFR80, or a cytoplasmic deletion form of TNFR80, reveal that inhibition of TNFR80 shedding by TAPI is independent of receptor phosphorylation and does not require the receptor cytoplasmic domain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7869036      PMCID: PMC2191902          DOI: 10.1084/jem.181.3.1205

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  26 in total

1.  Plasma tumor necrosis factor soluble receptors in chronic renal failure.

Authors:  M Brockhaus; Y Bar-Khayim; S Gurwicz; A Frensdorff; N Haran
Journal:  Kidney Int       Date:  1992-09       Impact factor: 10.612

2.  Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells.

Authors:  C F Ware; P D Crowe; T L Vanarsdale; J L Andrews; M H Grayson; R Jerzy; C A Smith; R G Goodwin
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

3.  A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact.

Authors:  C Perez; I Albert; K DeFay; N Zachariades; L Gooding; M Kriegler
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

4.  Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.

Authors:  T Gatanaga; C D Hwang; W Kohr; F Cappuccini; J A Lucci; E W Jeffes; R Lentz; J Tomich; R S Yamamoto; G A Granger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor.

Authors:  R A Heller; K Song; M A Onasch; W H Fischer; D Chang; G M Ringold
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.

Authors:  D Aderka; H Englemann; V Hornik; Y Skornick; Y Levo; D Wallach; G Kushtai
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

7.  Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha.

Authors:  B W Deleuran; C Q Chu; M Field; F M Brennan; T Mitchell; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1992-10

8.  Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.

Authors:  A P Cope; D Aderka; M Doherty; H Engelmann; D Gibbons; A C Jones; F M Brennan; R N Maini; D Wallach; M Feldmann
Journal:  Arthritis Rheum       Date:  1992-10

9.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

Authors:  K J Van Zee; T Kohno; E Fischer; C S Rock; L L Moldawer; S F Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

10.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.

Authors:  D Aderka; H Engelmann; Y Maor; C Brakebusch; D Wallach
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  53 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.

Authors:  P Fraticelli; M Sironi; G Bianchi; D D'Ambrosio; C Albanesi; A Stoppacciaro; M Chieppa; P Allavena; L Ruco; G Girolomoni; F Sinigaglia; A Vecchi; A Mantovani
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 3.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 4.  Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting.

Authors:  Georgina S Butler; Christopher M Overall
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

5.  Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide.

Authors:  I Walev; P Vollmer; M Palmer; S Bhakdi; S Rose-John
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 6.  Tumour necrosis factor and Crohn's disease.

Authors:  S J Van Deventer
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 7.  Membrane protein secretases.

Authors:  N M Hooper; E H Karran; A J Turner
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

8.  Enhanced potency of the metalloprotease inhibitor TAPI-2 by multivalent display.

Authors:  Aram J Raissi; Frank A Scangarello; Kaitlin R Hulce; Jason K Pontrello; Suzanne Paradis
Journal:  Bioorg Med Chem Lett       Date:  2014-02-14       Impact factor: 2.823

9.  IL-1beta augments TNF-alpha-mediated inflammatory responses from lung epithelial cells.

Authors:  Sara Saperstein; Linlin Chen; David Oakes; Gloria Pryhuber; Jacob Finkelstein
Journal:  J Interferon Cytokine Res       Date:  2009-05       Impact factor: 2.607

10.  Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma.

Authors:  Mohammad Fallahi-Sichani; Matthew A Schaller; Denise E Kirschner; Steven L Kunkel; Jennifer J Linderman
Journal:  PLoS Comput Biol       Date:  2010-05-06       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.